Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen’s Rare Disease pipeline – GlobeNewswire
Ipsen completes buyout of Memo Therapeutics AG, adding first-in-class asset to Ipsen's Rare Disease pipeline GlobeNewswire Source: news.google.com